Most Read Articles
Roshini Claire Anthony, 11 Dec 2020

Treatment with the nonsteroidal, selective mineralocorticoid receptor antagonist finerenone reduced chronic kidney disease (CKD) progression and cardiovascular (CV) event risk in patients with CKD and type 2 diabetes (T2D), according to the FIDELIO-DKD* study presented at ASN Kidney Week 2020.

Stephen Padilla, 22 Jun 2020
A dietary pattern (DP) characterized by high intakes of eggs, fish, milk, and other dairy products appears to confer protective benefits against incident cardiovascular disease (CVD) in women, reveals a study.

Empagliflozin near to us: Insights from its use in Asians

09 Jul 2020
In this fourth issue, join us as we discover the unique biology Asians have with respect to diabetes. Take a closer look at trials evaluating whether empagliflozin’s cardiovascular and renal benefits – as analysed in Asians – are consistent with the overall trial population, and how it addresses unmet needs.

Related MIMS Drugs

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Cardiology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Roshini Claire Anthony, 11 Dec 2020

Treatment with the nonsteroidal, selective mineralocorticoid receptor antagonist finerenone reduced chronic kidney disease (CKD) progression and cardiovascular (CV) event risk in patients with CKD and type 2 diabetes (T2D), according to the FIDELIO-DKD* study presented at ASN Kidney Week 2020.

Stephen Padilla, 22 Jun 2020
A dietary pattern (DP) characterized by high intakes of eggs, fish, milk, and other dairy products appears to confer protective benefits against incident cardiovascular disease (CVD) in women, reveals a study.